Oramed Pharmaceuticals Inc 2024年度报告

FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the Fiscal Year Ended December 31, 2024 or Securities registered pursuant to Section 12(b) of the Act: Securities registered pursuant to Section 12(g) of the Act: None.(Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the SecuritiesAct. YesNo Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of theAct. Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) ofthe Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrantwas required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or forsuch shorter period that the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment ofthe effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financialstatements of the registrant included in the filing reflect the correction of an error to previously issued financialstatements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis ofincentive-based compensation received by any of the registrant’s executive officers during the relevant recoveryperiod pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo The aggregate market value of the voting and non-voting common equity held by non-affiliates as of the lastbusiness day of the registrant’s most recently completed second fiscal quarter was $131,190,607 based on a price of$3.58, being the last price at which the shares of the registrant’s common stock were sold on the Nasdaq CapitalMarket prior to the end of the most recently completed second fiscal quarter. As of March 27, 2025, the registrant had 40,850,455 shares of common stock issued and outstanding. PART IVITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES67ITEM16.FORM10-KSUMMARY73 INTRODUCTION AND USE OF CERTAIN TERMS As used in this Annual Report on Form 10-K, the terms “we,” “us,” “our,” the “Company,” and “Oramed”mean Oramed Pharmaceuticals Inc. and our wholly-owned subsidiaries, unless otherwise indicated. All dollaramounts refer to U.S. dollars unless otherwise indicated. On December 31, 2024, the exchange rate between the New Israeli Shekel, or NIS, and the dollar, asquoted by the Bank of Israel, was NIS 3.647 to $1.00. Unless indicated otherwise by the context, statements in thisAnnual Report on Form 10-K that provide the dollar equivalent of NIS amounts or provide the NIS equivalent ofdollar amounts are based on such exchange rate. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS The statements contained in this Annual Report on Form 10-K that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federalsecurities laws and the Israeli securities law. Words such as “expects,” “anticipates,” “intends,” “plans,” “plannedexpenditures,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended toidentify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this Annual Report on Form 10-K. Additionally, statements concerning futurematters are forward-looking statements. We remind readers that forward-looking statements are merely predictionsand therefore inherently subject to uncertainties and other factors and involve known and unknown risks that couldcause the actual re